Axsome Therapeutics Inc.
Axsome Therapeutics Reports Strong Q4 and Full Year 2025 Financial Results
Summary
On February 23, 2026, Axsome Therapeutics, Inc. reported its financial results for the fourth quarter and full year 2025, demonstrating robust growth across its product portfolio. Total net product revenue for Q4 was $196.0 million, a 65% increase year-over-year, and $638.5 million for the full year, a 66% increase. AUVELITY, the company's flagship product, saw net product sales of $155.1 million in Q4 and $507.1 million for the full year, with year-over-year growth of 68% and 74%, respectively. SUNOSI net product revenue grew by 40% in Q4 and 32% for the full year. The company also announced the recent launch of SYMBRAVO and provided updates on its development pipeline, including the acceptance of a sNDA for AXS-05 for Alzheimer's disease agitation by the FDA. Axsome's cash position at December 31, 2025, was $322.9 million, and the company believes its current cash is sufficient to fund operations into cash flow positivity.
Profitelligence Alerts
Get alerts for AXSM
Be first to know when Axsome Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Axsome Therapeutics Inc.
Axsome Therapeutics Inc. specializes in the development and commercialization of transformative therapies for central nervous system (CNS) disorders. The company's focus is on addressing unmet medical needs in the fields of depression, migraines, and agitation associated with Alzheimer's disease, among other CNS conditions. Axsome's robust pipeline includes both clinical and preclinical stage compounds, highlighting a commitment to innovation and efficacy. By utilizing novel mechanisms of action, their product candidates aim to offer significant advantages over existing treatments. Axsome Therapeutics plays a crucial role in the pharmaceutical and healthcare sectors, helping reshape treatment paradigms for complex and challenging CNS disorders. Through strategic collaborations and leveraging cutting-edge research methods, the company seeks to provide effective healthcare solutions and improve quality of life for patients globally. Established on a vision to impact lives positively, Axsome continues to advance its clinical programs and regulatory approvals, thereby reinforcing its position in the biotechnology industry.
Official SEC Documents
Advertisement